Company intelligence / Profile preview

MediMabs

Montreal, Quebec, Canadamedimabs.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

MediMabs provides custom antibody development services for research applications. The company does not have its own clinical pipeline but supports academic and industry R&D through high-quality antibodies. It has partnered with Intellistem to offer advanced epitope mapping platforms. No direct clinical results as it does not develop drugs itself.

Therapeutic areas: Other
Modalities: Monoclonal antibodyRecombinant proteinSynthetic peptide
Industry: Drug Discovery Services

Partnerships

Intellistem (for IntelliPeptidome™ platform)

Beyond the preview

Go deeper on MediMabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MediMabs.

Explore the full profile